Amphastar Q2 revenue $182.4M, adjusted EPS $0.94; both up ~25-45% YoY

Amphastar Pharmaceuticals, Inc.

2024-Q2 EPS reported $1.54 revenue$354,230,000

Net revenues $182.4M (Q2) vs $145.7M YoY; six-month $354.2M vs $285.7M.
GAAP net income $37.9M ($0.73 diluted EPS) vs $26.1M ($0.49) YoY.
Adjusted non-GAAP net income $48.7M ($0.94 diluted EPS) vs $34.8M ($0.65) YoY.
CEO highlighted BAQSIMI as a leading portfolio driver amid transition to branded/biosimilar products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.